Indian pharmaceuticals major Lupin on Tuesday said it had acquired the rights for Antara, a drug to treat high blood cholesterol and high triglycerides, for $38.61 million from the US-based Oscient Pharmaceuticals.

The rights for the drug, along with related assets and inventories, have been acquired under the procedures of the US Bankruptcy Court, the company said in a regulatory filing with the Bombay Stock Exchange (BSE).